Retrograde degeneration in the optic pathway refers to the process whereby damage to neurons farther along the visual tract causes progressive injury “upstream,” toward the eye itself. This phenomenon leads to gradual loss of retinal ganglion cells (RGCs), optic nerve fibers, and even changes in the retina. Understanding retrograde degeneration is vital because it contributes to vision loss in a range of disorders—from glaucoma and optic neuritis to brain tumors and stroke.
Retrograde degeneration refers to the progressive atrophy of neurons and their connections that occurs “backwards” from an injury site toward the cell body. In the optic pathway, damage to the optic nerve or higher visual centers (for example in glaucoma, optic neuritis, or compressive lesions) triggers a cascade of molecular events—loss of neurotrophic support, activation of apoptotic pathways, and chronic inflammation—that leads to shrinkage and death of retinal ganglion cell axons and their parent cell bodies in the retina. Over weeks to months, this process impairs signal transmission from the eye to the brain, resulting in gradual vision loss. The hallmark features include narrowing of the retinal nerve fiber layer on optical coherence tomography, optic disc pallor on fundus exam, and corresponding visual field defects (e.g., arcuate scotomas) in perimetry.
Retrograde degeneration is the dying back of a neuron’s structure—from its axon terminal toward its cell body—after a lesion disrupts normal signaling. In the optic pathway (which runs from the retina through the optic nerves, chiasm, tracts, and radiations to the visual cortex), a lesion anywhere along this route can trigger neuronal self-destruction upstream. For example, a stroke damaging the lateral geniculate nucleus (LGN) can lead to apoptosis (programmed cell death) of retinal ganglion cells whose axons synapse there. Over weeks to months, this lost neural input causes thinning of the retinal nerve fiber layer and optic disc pallor—changes visible on imaging and clinical exam.
At the cellular level, retrograde degeneration involves interruption of neurotrophic support (growth factors needed for neuron survival), axonal transport failure, and activation of molecular pathways (like caspases) that dismantle the neuron’s cytoskeleton and nucleus. As the injury cascade unfolds, affected neurons shrink, lose synaptic connections, and eventually die. This mechanism contrasts with Wallerian (anterograde) degeneration, in which the segment of the axon beyond (distal to) the injury site degenerates. In retrograde degeneration, the portion of the neuron closer (proximal) to the cell body is lost.
Types of Retrograde Degeneration
Several patterns of retrograde degeneration occur in the visual system:
Primary Axonal Retrograde Degeneration
Occurs immediately when an axonal lesion severs the optic nerve fiber. The loss of axonal continuity triggers molecular pathways that cause the RGC cell body to degenerate over days to weeks.
Secondary (Wallerian-like) Retrograde Degeneration
Follows an initial Wallerian (distal) degeneration after severe injury. As distal segments break down, toxic byproducts and inflammatory signals travel back to the soma, inducing cell death.
Transsynaptic Retrograde Degeneration
Occurs when a lesion lies postsynaptic to the RGCs (for example, in the LGN or visual cortex). Loss of synaptic input leads to gradual “dying back” of upstream neurons, even though their axons are intact.
Acute vs. Chronic Retrograde Degeneration
Acute degeneration follows a sudden injury (trauma, stroke) and evolves rapidly.
Chronic degeneration arises from long-standing or progressive disorders (e.g., multiple sclerosis, glaucoma), leading to slow but cumulative neuron loss.
Isolated vs. Diffuse Retrograde Degeneration
Isolated affects a localized set of fibers (e.g., optic nerve head).
Diffuse involves widespread portions of the pathway (e.g., bilateral LGN injury), often seen in systemic or metabolic diseases.
Causes of Retrograde Degeneration in the Optic Pathway
Below are 15 common triggers for retrograde degeneration, each capable of disrupting optic pathway integrity and depriving RGCs of essential support:
Glaucoma
Chronic elevation of intraocular pressure compresses the optic nerve head, impairing axoplasmic flow and causing gradual RGC loss upstream.
Optic Neuritis
Autoimmune-mediated inflammation of the optic nerve (often in multiple sclerosis) damages myelin and axons, leading to both anterograde and retrograde neuronal death.
Ischemic Optic Neuropathy
Insufficient blood flow (arteritic or non-arteritic) to the optic nerve head causes infarction of axons and triggers retrograde cell body degeneration.
Optic Nerve Compression
Tumors (e.g., meningioma), aneurysms, or cysts can physically compress the optic nerve, disrupting axonal transport and initiating neuron death.
Traumatic Optic Neuropathy
Head or orbital trauma shears or impinges optic nerve fibers, interrupting signals and inducing retrograde apoptosis in RGCs.
Brain Tumors (LGN or Visual Cortex)
Space-occupying lesions in the LGN or occipital lobe deprive RGCs of synaptic targets, triggering transsynaptic degeneration.
Stroke
Infarction of the retrochiasmal visual pathway (optic tract, radiations, or cortex) leads to downstream loss of neuronal support and upstream RGC death.
Multiple Sclerosis
Recurrent demyelinating lesions can injure optic nerve and tract axons episodically, causing cumulative retrograde damage.
Leber’s Hereditary Optic Neuropathy (LHON)
A mitochondrial DNA mutation leads to RGC vulnerability; axonal injury and metabolic failure drive retrograde degeneration.
Radiation-Induced Optic Neuropathy
High-dose cranial irradiation injures optic nerves or chiasm, impairing neuron viability over months to years.
Nutritional Deficiencies (B12, Folate)
Inadequate B-vitamin levels impair myelin maintenance and axonal transport, leading to optic nerve demyelination and retrograde loss.
Toxic Optic Neuropathy
Exposure to toxins (methanol, ethambutol, tobacco/alcohol) damages mitochondria in RGCs and interrupts axon health, causing degeneration.
Hereditary Spastic Paraplegia
Genetic mutations affecting axonal transport machinery can include optic pathway involvement, resulting in retrograde degeneration alongside motor symptoms.
Neurosyphilis and Other Infections
Infectious agents can invade the optic pathway, causing inflammation, vaso-occlusion, and downstream neuronal loss.
Paraneoplastic Syndromes
Remote effects of cancer (e.g., anti-CRMP5 antibodies) target optic neurons, leading to retrograde cell death.
Symptoms of Retrograde Degeneration in the Optic Pathway
Retrograde degeneration produces a spectrum of visual and neurologic signs. Ten key symptoms include:
Decreased Visual Acuity
Gradual blurring or loss of sharpness, as RGCs and their fibers drop out.
Visual Field Defects
Partial loss of peripheral or central vision, depending on which fibers degenerate.
Optic Disc Pallor
Clinical finding of a pale optic nerve head on fundoscopy, reflecting loss of nerve fibers.
Relative Afferent Pupillary Defect (RAPD)
An asymmetric pupil response when light is swung between eyes, indicating upstream axonal loss.
Color Vision Deficits
Difficulty distinguishing reds and greens, due to loss of small, myelinated fibers carrying color information.
Contrast Sensitivity Reduction
Trouble seeing objects that blend into backgrounds, as overall signal strength from dying RGCs decreases.
Delayed Visual Evoked Potentials
Neurophysiological evidence of slowed signal conduction, manifesting as delays in cortical responses.
Photopsias
Perception of flashes of light, possibly from dying neurons firing aberrantly.
Ocular Discomfort or Pain
Mild ache, especially with eye movement, if inflammation accompanies the degeneration.
Progressive Night Vision Impairment
Difficulty seeing in dim light, reflecting loss of overall retinal signaling capacity.
Diagnostic Tests for Retrograde Degeneration
A combination of bedside exams, lab tests, electrophysiology, and imaging confirms the diagnosis and localizes the lesion. Below are 20 key tests, grouped by type.
Physical Examination
Visual Acuity Testing
Uses Snellen or LogMAR charts to quantify central vision loss.
Pupillary Light Reflex
Shining light in each eye to observe direct and consensual responses; helps detect afferent pathway defects.
Swinging Flashlight Test
Rapidly moving a light between pupils to elicit a relative afferent pupillary defect.
Ocular Motility Exam
Assessing eye movements to rule out coexisting cranial nerve or extraocular muscle involvement.
Manual Tests
Confrontation Visual Field Testing
Comparing patient’s peripheral vision to examiner’s to detect field defects at bedside.
Ishihara Color Plates
Standardized booklets for red-green color deficiency screening.
Amsler Grid Test
A simple dot-matrix grid held at reading distance to reveal central scotomas or distortions.
Red Desaturation Test
Comparing perceived color intensity of a red object between eyes; subtle indicator of optic nerve dysfunction.
Laboratory & Pathological Tests
Complete Blood Count (CBC) & ESR/CRP
Screens for anemia, infection, or inflammation that may underlie ischemic or inflammatory optic neuropathy.
Autoimmune Panel (ANA, anti-AQP4, anti-MOG)
Detects antibodies associated with neuromyelitis optica or other demyelinating diseases.
Infectious Serologies (Syphilis, Lyme Disease)
Identifies treatable infectious causes of optic nerve inflammation.
Cerebrospinal Fluid (CSF) Analysis
Examines cell counts, protein, oligoclonal bands, and infectious markers when central lesions are suspected.
Electrodiagnostic Tests
Visual Evoked Potential (VEP)
Measures cortical responses to visual stimuli; delayed P100 latency indicates demyelination or axonal loss.
Pattern VEP
More sensitive VEP subtype using reversing checkerboard patterns to localize conduction delays.
Multifocal VEP (mfVEP)
Records responses from different retinal areas simultaneously, mapping functional deficits.
Electroretinography (ERG)
Evaluates outer retina function to exclude primary retinal disease, ensuring defects are optic nerve–mediated.
Imaging Tests
Magnetic Resonance Imaging (MRI) of Brain and Orbits
High-resolution images to detect lesions in the optic nerve, chiasm, tract, LGN, or visual cortex; contrast enhancement reveals active inflammation.
Computed Tomography (CT) Scan
Faster imaging for acute trauma or when MRI is contraindicated; good for detecting bone fractures or calcified lesions.
Optical Coherence Tomography (OCT)
Non-invasive cross-sectional imaging of retinal layers; quantitatively measures thinning of the retinal nerve fiber layer and ganglion cell complex.
B-Scan Ocular Ultrasound
Assesses structural integrity of the globe and optic nerve sheath, useful in media opacities or orbital fractures.
Non-Pharmacological Treatments
Below are twenty supportive therapies—grouped into Exercise, Mind-Body, and Educational Self-Management—each described with its purpose and how it may slow or mitigate retrograde degeneration.
Aerobic Exercise (e.g., brisk walking, cycling)
Description & Purpose: Regular moderate aerobic workouts boost overall blood flow, including to the retina and optic nerve head, delivering essential oxygen and nutrients.
Mechanism: Exercise increases cardiac output and induces vasodilator release (nitric oxide), which helps maintain microvascular perfusion around vulnerable optic nerve fibers.Resistance Training (light weights, bands)
Description & Purpose: Strength training exercises help preserve muscle mass and regulate blood pressure, reducing vascular stress on optic nerve capillaries.
Mechanism: Improves endothelial function and reduces arterial stiffness via shear stress–mediated nitric oxide production.Balance & Coordination Drills (e.g., tai chi stances)
Description & Purpose: Enhances neurological connectivity and proprioceptive feedback, indirectly supporting central nervous system health.
Mechanism: Activates cerebellar and cortical circuits, promoting neurotrophic factor release (BDNF) that may have retrograde benefits for retinal neurons.Ocular Exercise (e.g., saccade training)
Description & Purpose: Trains eye-movement control, stimulating visual pathways to maintain synaptic activity.
Mechanism: Repetitive saccades increase neuronal firing in retinal ganglion cells, potentially delaying atrophy through “use-it-or-lose-it” plasticity.Vestibular Training (e.g., head turns with fixation)
Description & Purpose: Engages oculomotor and vestibular nuclei, enhancing cross-talk with visual pathways.
Mechanism: Co-activation of vestibulo-ocular reflex circuits can promote adaptive neural remodeling.Guided Meditation
Description & Purpose: Teaches relaxation, reduces stress hormones that can exacerbate neuroinflammation.
Mechanism: Lowers cortisol levels, which in excess can promote microglial activation and neuronal apoptosis.Mindful Breathing Exercises
Description & Purpose: Simple breath training to enhance parasympathetic tone and ocular blood flow regulation.
Mechanism: Increases vagal activity, reducing sympathetic vasoconstriction in choroidal and optic nerve head vessels.Progressive Muscle Relaxation
Description & Purpose: Systematically tensing and releasing muscle groups to ease systemic tension.
Mechanism: Reduces circulating catecholamines, decreasing oxidative stress that can harm retinal ganglion cells.Cognitive Behavioral Therapy (CBT)
Description & Purpose: Helps patients cope with vision changes, improving adherence to visual hygiene practices.
Mechanism: Reframes negative thoughts, reducing stress-related neurotoxic signaling.Biofeedback (e.g., heart rate variability training)
Description & Purpose: Teaches control over physiological functions (blood pressure), offering indirect optic nerve protection.
Mechanism: Real-time feedback fosters autonomic balance, preserving microvascular perfusion.Educational Workshops
Description & Purpose: Group sessions teaching disease mechanisms, self-monitoring vision changes, and lifestyle modifications.
Mechanism: Knowledge empowerment boosts early detection of progression and consistent engagement in protective behaviors.Self-Management Coaching
Description & Purpose: One-on-one counseling focusing on goals like smoking cessation or glucose control.
Mechanism: Personalized plans improve systemic health factors (blood sugar, lipids) that influence optic nerve vulnerability.Vision Rehabilitation Training
Description & Purpose: Occupational therapists teach strategies—eccentric viewing, contrast enhancement—to maximize remaining vision.
Mechanism: Enhances cortical plasticity, optimizing use of intact neural pathways.Peer-Support Groups
Description & Purpose: Regular meetings with others facing vision loss to share coping strategies.
Mechanism: Social support reduces stress, indirectly mitigating neuroinflammatory cascades.Guided Imagery
Description & Purpose: Visualization techniques to foster relaxation and healing focus.
Mechanism: Activates cortical areas linked to autonomic regulation, lowering excitotoxic risk.Educational E-Materials (videos, apps)
Description & Purpose: Interactive digital resources teaching eye-healthy habits—eyestrain breaks, lighting adjustments.
Mechanism: Frequent reminders translate into sustained behavioral change, preserving visual function.Structured Daily Routines
Description & Purpose: Consistent schedules for sleep, meals, and vision-rest breaks to stabilize circadian rhythms.
Mechanism: Regular melatonin cycles protect retinal cells from oxidative damage.Adaptive Technology Training
Description & Purpose: Instruction on magnifiers, screen-readers to reduce eye strain.
Mechanism: Minimizes compensatory overuse of damaged pathways, slowing stress-induced degeneration.Nutritional Counseling Workshops
Description & Purpose: Group classes teaching antioxidant-rich diets for ocular health.
Mechanism: Increases systemic levels of lutein, zeaxanthin, and vitamins that neutralize free radicals.Self-Monitoring Vision Logs
Description & Purpose: Daily journals of vision clarity, headaches, and eye discomfort to detect early deterioration.
Mechanism: Timely identification of changes enables prompt medical adjustments, curbing further retrograde loss.
Evidence-Based Drugs
Below are ten pharmacologic agents shown to offer neuroprotective or disease-modifying benefit in conditions featuring retrograde optic degeneration. Each entry includes drug class, typical dosage, timing, and key side effects.
Memantine
Class: NMDA-receptor antagonist
Dosage & Timing: 5 mg once daily for 1 week, then 10 mg once daily; taken in morning with food
Side Effects: Dizziness, headache, constipation
Brimonidine Tartrate
Class: Alpha-2 adrenergic agonist (topical eye drops)
Dosage & Timing: 0.2% solution, one drop in each eye twice daily (8 am, 8 pm)
Side Effects: Ocular hyperemia, dry mouth, fatigue
Citicoline (CDP-Choline)
Class: Neurotrophic supplement
Dosage & Timing: 500 mg oral tablet twice daily after meals
Side Effects: Upset stomach, insomnia
Riluzole
Class: Glutamate release inhibitor
Dosage & Timing: 50 mg twice daily (at least 12 hours apart)
Side Effects: Nausea, elevated liver enzymes, dizziness
Nimodipine
Class: Calcium channel blocker
Dosage & Timing: 60 mg every 4 hours for 21 days (used off-label for neuroprotection)
Side Effects: Headache, hypotension, flushing
Alpha-Lipoic Acid
Class: Antioxidant
Dosage & Timing: 600 mg oral once daily
Side Effects: Skin rash, mild GI upset
Valproic Acid
Class: HDAC inhibitor with neuroprotective properties
Dosage & Timing: 250 mg twice daily (titrate slowly)
Side Effects: Weight gain, tremor, hepatotoxicity
Erythropoietin (EPO)
Class: Cytokine with neurotrophic effects
Dosage & Timing: 30,000 IU subcutaneously weekly (investigational)
Side Effects: Hypertension, risk of thrombosis
Minocycline
Class: Tetracycline antibiotic with anti-inflammatory/neuroprotective action
Dosage & Timing: 100 mg twice daily for 3–6 months
Side Effects: Photosensitivity, vestibular issues
Omega-3 Fish Oil (EPA/DHA)
Class: Polyunsaturated fatty acids
Dosage & Timing: 1,000 mg combined EPA/DHA daily with meals
Side Effects: Fishy aftertaste, mild GI discomfort
Dietary Molecular Supplements
These ten nutraceuticals support retinal and optic nerve health by targeting oxidative stress, mitochondrial function, or inflammation.
Lutein
Dosage: 10 mg daily
Function: Accumulates in retina as blue-light filter
Mechanism: Scavenges reactive oxygen species
Zeaxanthin
Dosage: 2 mg daily
Function: Complementary macular antioxidant
Mechanism: Protects photoreceptor membranes
Vitamin B12 (Methylcobalamin)
Dosage: 1,000 µg daily
Function: Supports myelin maintenance
Mechanism: Methyl donor for neuronal repair
Coenzyme Q10
Dosage: 100 mg twice daily
Function: Enhances mitochondrial ATP generation
Mechanism: Electron‐carrier in respiratory chain
Ginkgo Biloba Extract
Dosage: 120 mg daily (standardized to 24% flavone glycosides)
Function: Improves microcirculation
Mechanism: Vasodilates via nitric oxide pathways
Alpha-Lipoic Acid
Dosage: 600 mg daily
Function: Universal antioxidant
Mechanism: Recycles vitamins C & E, chelates metals
Resveratrol
Dosage: 150 mg daily
Function: Activates SIRT1, promotes cell survival
Mechanism: Inhibits NF-κB-mediated inflammation
Curcumin (with Piperine)
Dosage: 500 mg curcumin + 5 mg piperine daily
Function: Anti-inflammatory, antioxidant
Mechanism: Blocks COX‐2 and lipoxygenase
Magnesium Citrate
Dosage: 200 mg elemental magnesium nightly
Function: Stabilizes neuronal membranes
Mechanism: NMDA‐receptor modulation
N-Acetylcysteine (NAC)
Dosage: 600 mg twice daily
Function: Precursor to glutathione
Mechanism: Replenishes intracellular antioxidant stores
Advanced Biologic & Regenerative Agents
Clodronate (Bisphosphonate)
Dosage: 100 mg IV monthly
Function: Inhibits microglial activation
Mechanism: Blocks ATP analogues that drive inflammation
Recombinant Human Nerve Growth Factor (rhNGF)
Dosage: 20 µg intravitreal injection biweekly (investigational)
Function: Promotes retinal ganglion cell survival
Mechanism: Binds TrkA receptors, activating pro-survival pathways
Platelet-Rich Plasma (PRP)
Dosage: 0.1 mL perineural injection monthly
Function: Delivers concentrated growth factors
Mechanism: Releases PDGF, VEGF, and TGF-β to support repair
Hyaluronic Acid (Viscosupplementation)
Dosage: 0.05 mL perineural injection monthly
Function: Provides mechanical cushioning in optic canal
Mechanism: Restores normal extracellular matrix viscosity
Autologous Mesenchymal Stem Cells
Dosage: 1×10⁶ cells injected perineurally once every 3 months
Function: Differentiate into supportive glial cells
Mechanism: Release trophic factors (BDNF, CNTF) to rescue neurons
Erythropoietin Analogs (e.g., Carbamylated EPO)
Dosage: 10,000 IU SC weekly
Function: Neuroprotection without erythropoiesis
Mechanism: Activates EPOR–βcR heterocomplex, inhibiting apoptosis
Surgical Interventions
Optic Nerve Sheath Fenestration
Procedure: Window creation in the dural sheath around optic nerve via orbitotomy
Benefits: Lowers perineural pressure, restores axoplasmic flow
Transorbital Neuroendoscopic Decompression
Procedure: Endoscopic removal of compressive lesions (e.g., meningioma)
Benefits: Minimally invasive, precise lesion resection
Glaucoma Filtration Surgery (Trabeculectomy)
Procedure: Creates alternate aqueous outflow path to lower IOP
Benefits: Slows pressure-induced axonal damage
Orbital Decompression Surgery
Procedure: Resection of orbital walls to reduce optic canal pressure (e.g., in thyroid eye disease)
Benefits: Rapid relief of compressive ischemia
Vitrectomy with Internal Limiting Membrane Peel
Procedure: Removes vitreous traction near optic disc
Benefits: Prevents secondary stress on optic nerve fibers
Key Prevention Strategies
Control Intraocular Pressure
Maintain Healthy Blood Sugar & Pressure
Quit Smoking
Limit Alcohol & Neurotoxins
Wear Protective Eyewear
Follow a Diet Rich in Antioxidants
Exercise Regularly
Manage Obstructive Sleep Apnea
Avoid Head Trauma
Schedule Annual Eye Exams
When to See a Doctor
Sudden or rapidly worsening vision loss
Persistent eye pain or headache with eye movement
New visual field defects (dark spots, tunnel vision)
Optic disc swelling noted on exam
Any sign of neuro-ophthalmic emergency (e.g., giant cell arteritis symptoms—jaw claudication, scalp tenderness)
“Do’s” and “Don’ts”
Do:
Keep regular ophthalmology appointments
Adhere strictly to prescribed eye drops
Maintain cardiovascular health
Track vision changes daily
Practice safe screen use (20-20-20 rule)
Don’t:
Skip follow-up visits when vision feels stable
Self-medicate with unverified supplements
Overuse digital devices without breaks
Expose eyes to harsh chemicals or UV without protection
Ignore systemic symptoms (e.g., giant cell arteritis signs)
Frequently Asked Questions
What causes retrograde degeneration in the optic pathway?
Damage to axons—due to glaucoma, inflammation, or compression—cuts off trophic support, triggering neuronal death.Can vision loss from retrograde degeneration be reversed?
Full reversal is rare once neurons die; early intervention can preserve remaining function.How quickly does degeneration occur?
It varies: acute injuries may show changes within days, while chronic conditions progress over months to years.Are there biomarkers for early detection?
Elevated neurofilament light chain in serum or tears and OCT thinning of the nerve fiber layer can be early indicators.Is exercise really helpful?
Yes—regular exercise improves ocular blood flow and releases neurotrophic factors that support neurons.Which eye drops protect the optic nerve?
Brimonidine has evidence for modest neuroprotection beyond pressure lowering.What role do dietary supplements play?
Antioxidants (lutein, zeaxanthin) and mitochondrial cofactors (CoQ10) help neutralize damaging free radicals.When is surgery necessary?
In cases of compressive lesions, uncontrolled intraocular pressure, or acute vision threats to relieve pressure.Can stem cell therapy restore vision?
Research is ongoing; small trials show promise in halting progression, but routine use is not yet established.How often should I monitor my vision?
Daily self-checks of acuity and field; formal perimetry every 3–6 months if at high risk.Does caffeine affect the optic nerve?
Moderate intake appears neutral; excessive caffeine may transiently raise IOP in sensitive individuals.Are there genetic tests for susceptibility?
Certain gene variants (e.g., OPTN in normal-tension glaucoma) can increase risk but are not routine.Can mindfulness meditation slow neurodegeneration?
By reducing stress hormones, it may lower inflammation that contributes to neuronal loss.Is occupational therapy useful?
Yes—vision rehabilitation teaches strategies that maximize remaining sight for daily activities.What new treatments are on the horizon?
Gene therapy, targeted neurotrophic delivery (e.g., intravitreal NGF), and novel small molecules that block apoptosis are in early clinical trials.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: July 13, 2025.
